Exploring Parkinson-associated kinases for CRISPR/Cas9-based gene editing: beyond alpha-synuclein

Area of Science:

• Neuroscience
• Genetics
• Biotechnology

Background:

• Parkinson's disease (PD) involves dopaminergic neuron loss and motor impairment.
• Familial PD is linked to mutations in genes like SNCA, PINK1, LRRK2, and DJ-1.
• Kinase dysregulation is implicated in PD pathogenesis.

Purpose of the Study:

• To review the CRISPR/Cas9 genome editing system's structure, function, and history.
• To summarize kinases involved in PD pathogenesis targeted by CRISPR/Cas9.
• To explore novel kinase targets and address CRISPR/Cas9 challenges in PD research.

Main Methods:

• Review of CRISPR/Cas9 technology and its application in PD research.
• Identification and summary of PD-related kinases targeted by CRISPR/Cas9 (e.g., LRRK2, PINK1).
• Discussion of potential novel kinase targets and CRISPR/Cas9 off-target effects.

Main Results:

• CRISPR/Cas9 technology is a rapidly advancing tool for neurodegenerative disease research.
• Several kinases (LRRK2, PINK1, PKC-γ, AMPK) are currently targeted for PD.
• Novel targets include GRKs, GAKs, CDK5, ATM, c-ABL, and RET receptors.

Conclusions:

• CRISPR/Cas9 technology holds significant potential for advancing PD research.
• Gene editing, alongside gene therapy, presents a promising therapeutic strategy for Parkinson's disease.
• Addressing off-target effects and challenges is crucial for efficient CRISPR/Cas9 application in PD.